AVIR

Atea Pharmaceuticals Inc

AVIR.US ateapharma.com
5.31
+0.13 (+2.51%)
USD · NASDAQ
52-week range
2.78
6.45
Trading at 69% of the 52-week range
Market Cap
425.89M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
2.55
Div. Yield
N/A
% Institutions
79.06%
% Insiders
13.37%

1 Year

+60.9%

3 Year

+61.4%

10 Year

-82.5%
Description

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Company Information

Company Name
Atea Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US04683R1068
CIK: 0001593899
CUSIP: 04683R106
Currency: USD
Full Time Employees: 55
Phone: 857 284 8891
Fiscal Year End: December
IPO Date: Oct 30, 2020
Description:

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Address:

225 Franklin Street, Boston, MA, United States, 02110

People

Directors & Officers

Name Title Year Born
Dr. Jean-Pierre Sommadossi Ph.D. Founder, Chairman, CEO & President 1956
Ms. Andrea J. Corcoran J.D. CFO, Executive VP of Legal & Secretary 1962
Mr. John F. Vavricka Chief Commercial Officer 1963
Dr. Janet M. J. Hammond M.D., Ph.D. Chief Development Officer 1960
Dr. Maria Arantxa Horga M.D. Chief Medical Officer 1968
Mr. Wayne Foster CPA Executive VP of Finance & Chief Accounting Officer 1969
Ms. Jonae R. Barnes Senior Vice President of Investor Relations & Corporate Communications NA
Mr. Adel Moussa Ph.D. Executive Vice President of Chemistry NA
Mr. Xiao-Jian Zhou Ph.D. Executive Vice President of Early Stage Development NA
Mr. Keith Pietropaolo Executive VP of Clinical Sciences & Project Management NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 10, 2024 Franklin M Berger N/A Sale 359.61K $2.85 $1.02M
Sep 19, 2024 Jean-Pierre Sommadossi N/A Sale 1.84K $4.00 $7.36K
Sep 17, 2024 Jean-Pierre Sommadossi N/A Sale 33.94K $4.05 $137.46K
Jun 20, 2024 Bruce Polsky N/A Sale 17.54K $3.49 $61.23K
Jun 05, 2024 Jean-Pierre Sommadossi N/A Sale 1.01K $4.00 $4.02K
Feb 01, 2024 Andrea Corcoran N/A Sale 15.84K $3.84 $60.84K
Feb 01, 2024 Jean-Pierre Sommadossi N/A Sale 56.91K $3.85 $219.10K
Feb 01, 2024 Wayne Foster N/A Sale 12.48K $3.84 $47.91K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 11.95M Mar 31, 2026 14.90% $0.00 23.47%
BlackRock Inc 8.44M Mar 31, 2026 10.52% $0.00 -0.66%
BML Capital Management LLC 6.95M Jun 30, 2026 8.67% $18.36 -1.51%
TANG CAPITAL MANAGEMENT LLC 4.81M Mar 31, 2026 6.00% $1.32 0.00%
Vanguard Capital Management, LLC 3.25M Mar 31, 2026 4.05% $0.00 0.00%
Bain Capital Life Sciences Investors, LLC 2.36M Mar 31, 2026 2.94% $1.15 -5.03%
Geode Capital Management, LLC 1.75M Mar 31, 2026 2.18% $0.00 -5.07%
State Street Corp 1.69M Mar 31, 2026 2.11% $0.00 -5.03%
Acadian Asset Management LLC 1.58M Mar 31, 2026 1.97% $0.01 10,689.48%
Two Sigma Investments LLC 1.51M Jun 30, 2026 1.88% $0.01 -19.18%
Dimensional Fund Advisors, Inc. 1.30M Jun 30, 2026 1.62% $0.00 3.51%
Rosalind Advisors, Inc. 1.17M Mar 31, 2026 1.46% $2.53 0.00%
Renaissance Technologies Corp 1.17M Mar 31, 2026 1.45% $0.01 -1.86%
JPMorgan Chase & Co 940.16K Mar 31, 2026 1.17% $0.00 -30.27%
Morgan Stanley - Brokerage Accounts 731.02K Mar 31, 2026 0.91% $0.00 11.42%
Curated Wealth Partners LLC 695.00K Jun 30, 2026 0.87% $0.09 0.00%
Charles Schwab Investment Management Inc 596.71K Mar 31, 2026 0.74% $0.00 -1.82%
The Goldman Sachs Group Inc 588.46K Mar 31, 2026 0.73% $0.00 24.54%
Northern Trust Corp 585.03K Mar 31, 2026 0.73% $0.00 4.43%
Vanguard Portfolio Management, LLC 557.58K Mar 31, 2026 0.70% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Growth Compy Commingled Pl S 6.54M 8.16% ▲ 0.00% Jul 31, 2026
2 Fidelity Growth Company Fund 3.10M 3.86% ▲ 0.00% Jul 31, 2026
3 Vanguard MStar Total Stk Mkt Idx Invest 2.03M 2.53% ▲ 0.00% Jul 31, 2026
4 iShares Russell 2000 ETF 1.81M 2.25% ▼ 0.57% Aug 31, 2026
5 Fidelity Growth Company K6 1.22M 1.52% ▲ 0.00% Jul 31, 2026
6 Vanguard Institutional Extnd Mkt Idx Tr 867.53K 1.08% ▲ 0.30% Jul 31, 2026
7 Fidelity Small Cap Index 769.17K 0.96% ▲ 10.08% Jun 30, 2026
8 Fidelity Series Growth Company 733.90K 0.92% ▲ 0.00% Jul 31, 2026
9 iShares Russell 2000 Value ETF 662.34K 0.83% ▼ 0.23% Aug 31, 2026
10 BlackRock Advantage Small Cap Core Instl 613.37K 0.76% ▲ 0.00% Jul 31, 2026

Financial Highlights

Market Cap: $425.89M
EBITDA: $-182.86M
Book Value: $2.55
Earnings/Share: $-2.08
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -36.72%
ROE (TTM): -58.14%
Revenue (TTM): $192.18M
Revenue/Share (TTM): $2.31
Earnings Growth (YOY): 264.10%
Revenue Growth (YOY): 295.20%

Valuation Metrics

Enterprise Value: $206.85M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 80.20M
Shares Float: 60.34M
% Insiders: 13.37%
% Institutions: 79.06%
Short % Float: 12.32%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-416.00K
Gross Profit
subtotal
$-416.00K
SG&A
adjust
$-32.86M
R&D
adjust
$-148.02M
Operating Income
subtotal
$-180.89M
Other / Non-Operating Items
adjust
$22.54M
Net Income
subtotal
$-158.35M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about AVIR.US!